Clinical Development Medical Director - EMEA / UK

About Us We are developing potentially best in class therapies for patients living with severe autoimmune diseases. Our lead antibody, claseprubart (DNTH103), is purposefully engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein that drives disease pathology – enabling less frequent and more convenient self-administered subcutaneous injections. Our second clinical candidate, DNTH212 is a first and potentially best in class, bifunctional inhibitor that targets clinically validated and complementary disease modifying mechanisms, Type 1 IFN suppression and B cell modulation – enabling potential for improved clinical outcomes and patient friendly convenient, self-administered subcutaneous injections. To learn more, please visit www.dianthustx.com and follow us on LinkedIn. About the Role We are seeking a dynamic and scientifically driven Clinical Development Medical Director to join our Medical Affairs team. Reporting to our Executive Medical Affairs Director, EMEA/UK Lead, this cross-functional role bridges clinical development and medical affairs, providing scientific and clinical leadership to support the advancement of our pipeline and the execution of medical strategies. The ideal candidate will bring strong clinical acumen, experience in rare diseases and/or autoimmunology, and a collaborative mindset to help drive impactful medical and scientific initiatives. Day to day you will support clinical trial executions and enrollment through strong Principal Investigator relationship building. This is an exciting opportunity to join a late-stage clinical company with pipeline of potential best in class autoimmune therapies. We are building a culture of individuals who hold our core principles at the center of our operations, with the goal to elevate the care of our patients’ lives. We are open to you working remotely. You must be located in the United Kingdom. Key Responsibilities Scientific & Clinical Leadership: Serve as a subject matter expert on the company’s pipeline assets, providing deep clinical and scientific insights. Support the development and execution of global medical affairs strategies, including evidence generation, scientific communications, and external engagement. Medical Affairs Support: Contribute to the development of medical education materials, scientific publications, and congress presentations. Collaborate with Medical Science Liaisons (MSLs) to ensure scientific alignment and support field medical activities. Participate in the planning and execution of advisory boards and KOL engagement initiatives. Clinical Development Interface: Act as a key liaison between Medical Affairs and Clinical Development, ensuring alignment on clinical trial design, data interpretation, and lifecycle planning. Provide medical input into clinical protocols, investigator brochures, and regulatory documents as needed. Evidence Generation: Support the design and execution of investigator-initiated studies (IIS), real-world evidence (RWE) programs, and post-marketing studies. Collaborate with cross-functional teams to identify data gaps and develop strategies to address them. Cross-Functional Collaboration: Work closely with Regulatory, Commercial, Market Access, and other internal stakeholders to ensure scientific consistency and strategic alignment. Contribute to launch readiness and lifecycle management planning. Experience MD, DO, or equivalent medical degree required; board certification in a relevant specialty preferred. Minimum 5–8 years of experience in the biopharmaceutical industry, with at least 3 years in a medical affairs or clinical development role. Experience in rare diseases and/or autoimmunology strongly preferred. Proven ability to interpret and communicate complex clinical data to diverse audiences. Strong interpersonal and communication skills, with a collaborative and proactive approach. Ability to thrive in a fast-paced, evolving environment with a high degree of autonomy. Ability to travel up to 50% including to company events, potential relevant conferences and clinically relevant trial sites.